Netherlands

VSY Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

A New Drug to Treat COVID-19, TR-C 19 is Now Ready for Human Testing

Lead Product(s): TR-C 19

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

VSY Biotechnology Research Center has developed a strong R&D program in various areas of biotechnology and is now proud to announce its latest achievement: TR-C 19, a drug to treat COVID-19.

Batavia Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

IAVI and Batavia Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines

Lead Product(s): VSV?G-SARS-CoV-2

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: IAVI

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 05, 2020

Details:

By working with Batavia Biosciences, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines, including vaccines against a group of viruses that cause hemorrhagic fevers and other emerging viral disease threats.

Khondrion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Khondrion Highlights Potential Role of Inflammatory Lipid Modulator Prostaglandin E2 In COVID-19

Lead Product(s): Sonlicromanol

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 15, 2020

Details:

Company’s lead asset sonlicromanol may have potential as a repurposed treatment for PGE2-driven inflammatory consequences underlying severe COVID-19 disease.